Breaking News Instant updates and real-time market news.

AMGN

Amgen

$184.86

-1.14 (-0.61%)

, ARRY

Array BioPharma

$19.37

-0.19 (-0.97%)

04:55
06/23/18
06/23
04:55
06/23/18
04:55

European Society for Medical Oncology (ESMO) to hold a conference

ESMO World Congress on Gastrointestinal Cancer 2018 will be held in Barcelona, Spain on June 20-23.

AMGN

Amgen

$184.86

-1.14 (-0.61%)

ARRY

Array BioPharma

$19.37

-0.19 (-0.97%)

BAYRY

Bayer

$0.00

(0.00%)

HALO

Halozyme

$18.07

-0.52 (-2.80%)

INCY

Incyte

$74.02

1.55 (2.14%)

LLY

Eli Lilly

$85.90

-0.17 (-0.20%)

MRK

Merck

$61.46

0.295 (0.48%)

SHPG

Shire

$161.73

-0.7 (-0.43%)

RHHBY

Roche

$0.00

(0.00%)

SNY

Sanofi

$39.98

0.96 (2.46%)

  • 23

    Jun

  • 28

    Jun

  • 30

    Jun

  • 30

    Jun

  • 10

    Sep

  • 20

    Oct

  • 23

    Oct

  • 28

    Oct

  • 21

    Dec

  • 28

    Jan

  • 22

    Mar

AMGN Amgen
$184.86

-1.14 (-0.61%)

06/12/18
LEER
06/12/18
NO CHANGE
LEER
Too early to see Allergan's atogepant threatening injectables, says Leerink
Leerink analyst Geoffrey Porges notes that Allergan (AGN) announced positive topline data from a phase IIb/III trial of oral CGRP receptor antagonist atogepant in episodic migraine prevention. The analyst believes this data is certainly positive for Allergan and suggests they may eventually have an oral CGRP medicine approval for both acute and preventative treatment of migraines, However, Porges awaits further data disclosure and larger patient numbers to be convinced about comparing the efficacy of atogepant to the more advanced injectable CGRP medicines in development. With regard to Amgen (AMGN) and Alder (ALDR), who both have injectable CGRP antibodies for migraine prevention, potential competitive erosion from orals is still several years away and he continues to see the more severe chronic migraine population as being a more meaningful commercial opportunity for this class.
06/05/18
MSCO
06/05/18
NO CHANGE
Target $50
MSCO
Overweight
Neulasta biosimilar could 'reignite' Mylan momentum, says Morgan Stanley
Morgan Stanley analyst David Risinger said FDA approval of Fulphila, Mylan's (MYL) biosimilar to Amgen's (AMGN) Neulasta, should be a "substantial and durable" profit opportunity and could "reignite" Mylan's upward momentum. He notes that Mylan anticipates launching Fulphila in the coming weeks and that the FDA biosimilar user fee act action date for Coherus' (CHRS) Neulasta biosimilar is November 3. Risinger has an Overweight rating and $50 price target on Mylan shares.
06/11/18
WELS
06/11/18
NO CHANGE
Target $240
WELS
Outperform
Allergan migraine data on lower end of relative efficiency, says Wells Fargo
Wells Fargo analyst David Maris says his initial review suggests Allergan's (AGN) atogepant's Phase IIb data are "relatively in-line but on the lower end of the efficacy" demonstrated by the calcitonin gene-related peptide migraine treatments in Phase III trials. Atogepant is expected to face competition from Amgen (AMGN)/Novartis (NVS), Eli Lilly (LLY) and Teva (TEVA), which are all developing injectable anti-CGRP treatments, as well as Alder Biopharmaceuticals (ALDR), which has an infusion-administered anti-CGRP in development, Maris tells investors in a research note. He notes that while Allergan will be following these competitors to the market, atogepant will be differentiated in that it is the only oral prophylactic anti-CGRP therapy. The analyst forecasts $75M in sales for atogepant in 2022. He does not believe many investors are giving Allergan credit for atogepant, meaning the "risk to the downside looks limited." Maris keeps an Outperform rating on Allergan shares.
06/22/18
MSCO
06/22/18
NO CHANGE
Target $200
MSCO
Overweight
Amgen may be pressured by IMS restatement for Aimovig, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison noted that IMS announced that it has overstated the mail order volume for Amgen's Aimovig and will amend its mail order method with this week's data and restate prior weeks next Friday. Preliminary figures indicate the restatement will lower overall total prescriptions by about 27%, said Harrison. He would expect pressure on Amgen shares given the perception negative, though he still thinks initial Aimovig demand is robust, Harrison tells investors. He keeps an Overweight rating and $200 price target on Amgen shares.
ARRY Array BioPharma
$19.37

-0.19 (-0.97%)

05/10/18
JPMS
05/10/18
NO CHANGE
JPMS
Array BioPharma added to Focus List at JPMorgan
06/15/18
PIPR
06/15/18
NO CHANGE
Target $21
PIPR
Overweight
Array should be bought ahead of June 30 PDUFA, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff is confident in Braftovi plus Mektovi approval in BRAF-mutant melanoma by the June 30 FDA action date. Array BioPharma presented at ASCO Phase III data showing median overall survival of 33.6 months for the combo versus 16.9 months for Zelboraf control, Tenthoff tells investors in a research note. This "best-in-class efficacy and tolerability will differentiate the combo on launch," the analyst contends. He recommends buying Array shares by June 30 and reiterates an Overweight rating on the name with a $21 price target.
05/10/18
JPMS
05/10/18
NO CHANGE
Target $185
JPMS
Overweight
Array BioPharma added to Analyst Focus List at JPMorgan
JPMorgan analyst Anupam Rama added Array BioPharma (ARRY) to his firm's Analyst Focus List as a growth strategy and reiterates an Overweight rating on the shares. The analyst lowered his price target for the stock to $18 from $19 after taking out MEK + I/O from his model. He believes, however, that Roche's (RHHBY) Phase 3 IMblaze370 trial failure was largely priced in. Rama recommends buying Array at current levels ahead of the "multiple" mid-year pipeline catalysts.
06/20/18
CANT
06/20/18
NO CHANGE
Target $24
CANT
Overweight
Array BioPharma shares could have more room to advance, says Cantor Fitzgerald
Cantor Fitzgerald analyst Mara Goldstein believes Array BioPharma's combination of binimetinib/encorafenib has the "potential to be best-in-class and take a market-leader position." The FDA action date is June 30. Further, the analyst sees opportunity in BRAF+ CRC based on the safety lead-in portion of the Beacon study, which she believes could expand the potential market, with updated results to be presented on June 23. Goldstein thinks Array shares "could have further room to advance" and keeps an Overweight rating on the name with a $24 price target.
BAYRY Bayer
$0.00

(0.00%)

12/29/17
JPMS
12/29/17
NO CHANGE
JPMS
Roche added to Analyst Focus List at JPMorgan
JPMorgan analyst Richard Vosser added Roche (RHHBY) to his firm's Analyst Focus List and keeps an Overweight rating on the shares with a SFR 300 price target. The analyst sees Roche as having the most significant earnings upside potential of any of the European large cap pharma stocks in 2018. He believes the potential of the company's pipeline is being underappreciated at current share levels. His top picks for 2018 are Roche and Bayer (BAYRY).
04/10/18
BMOC
04/10/18
DOWNGRADE
Target $128
BMOC
Market Perform
Monsanto downgraded to Market Perform at BMO Capital on Bayer deal prospects
As reported earlier, BMO Capital analyst Joel Jackson downgraded Monsanto (MON) to Market Perform from Outperform while keeping his $128 price target. Jackson cites the rising likelihood of the acquisition by Bayer (BAYRY) after yesterday's reports of approval of the merger by the U.S. Department of Justice. The analyst notes that since the stock price is now so close to Bayer's takeout price, the isn't "sufficient spread" to support a more bullish rating. In the event of a breakdown of the deal, Jackson sees downside support for the stock around $110 per share.
12/28/17
ARGS
12/28/17
NO CHANGE
Target $470
ARGS
Buy
Regeneron price target lowered to $470 from $540 at Argus
Argus analyst Jasper Hellweg lowered his price target on Regeneron (REGN) to $470 to reflect some of the recent weakness in the stock, but keeps his Buy rating. Hellweg says that while the company's growth has slowed in recent years, it continues to benefit from sales of Eylea, collaboration agreements with Sanofi (SNY) and Bayer (BAYRY) as well as a strong new product pipeline.
04/16/18
ARGS
04/16/18
DOWNGRADE
ARGS
Sell
Monsanto downgraded to Sell from Buy at Argus
Argus analyst Bill Selesky issued a double-notch downgrade on Monsanto (MON) to Sell from Buy after the U.S. Justice Department approved its acquisition by Bayer (BAYRY) last week. The analyst says the deal is expected to be further approved by Canadian and Mexican regulators and completed by the end of Q2. As part of the approval, the analyst points to the companies' pledge to sell additional assets even as Monsanto stock trades just below Bayer's acquisition price of $128 per share.
HALO Halozyme
$18.07

-0.52 (-2.80%)

02/21/18
ADAM
02/21/18
NO CHANGE
Target $21
ADAM
Buy
Halozyme pipeline progress leads to price target increase at Canaccord
Canaccord analyst Arlinda Lee raised her price target on Halozyme to $21 from $19 citing its pipeline progress and steady Enhanze progress. Lee reiterated her Buy rating on Halozyme shares.
01/24/18
GSCO
01/24/18
INITIATION
Target $20
GSCO
Neutral
Halozyme initiated with a Neutral at Goldman Sachs
Goldman analyst Dana Flanders initiated Halozyme with a Neutral and $20 price target.
05/11/18
LEHM
05/11/18
DOWNGRADE
Target $19
LEHM
Underweight
Halozyme downgraded to Underweight from Equal Weight at Barclays
Barclays analyst Gena Wang downgraded Halozyme Therapeutics to Underweight with a $19 price target. The analyst sees limited upside to revenue estimates in 2018 and "high risk" for the company's Phase 3 readout in pancreatic cancer.
01/24/18
DBAB
01/24/18
NO CHANGE
Target $21
DBAB
Buy
Halozyme target raised to $21 after investor meetings at Deutsche Bank
Deutsche Bank analyst Andrew Peters raised his price target for Halozyme shares to $21 from $19 after hosting investor meetings with management. The meetings offered a "robust reminder" of the strength of the company's dual-pillar strategy, Peters tells investors in a research note. The analyst believes Halozyme's Enhanze platform continues to be underappreciated by investors. He reiterates a Buy rating on the shares.
INCY Incyte
$74.02

1.55 (2.14%)

06/01/18
PIPR
06/01/18
NO CHANGE
PIPR
Overweight
Piper says Lilly should get some share for Olumiant with aggressive pricing
Piper Jaffray analyst Tyler Van Buren noted that the TNF step-through for Incyte (INCY) and Eli Lilly's (LLY) Olumiant potentially decreases the overall market opportunity, but he believes Olumiant will get some share of TNF failure patients given that Lilly announced it is pricing the drug "aggressively" at a potential 60% price discount to AbbVie's (ABBV) Humira. Van Buren estimates this price to be a potential 50% price discount to the other oral JAK approved for RA, Pfizer's (PFE) Xeljanz. The analyst keeps an Overweight rating on Incyte, citing the durable revenue base through the late 2020s that should come from Olumiant along with the "significant potential" he sees in its pipeline opportunities.
06/15/18
PIPR
06/15/18
NO CHANGE
Target $85
PIPR
Overweight
Piper Jaffray sees better than expected U.S. launch for Olumiant
Piper Jaffray analyst Tyler Van Buren says he left a meeting with CEO of Eli Lilly (LLY) David Ricks with increased conviction in the U.S. launch of Olumiant. The analyst believes the launch will be better than investors currently anticipate and reiterates an Overweight rating on shares of Incyte (INCY) with an $85 price target. Van Buren expect payors to be "very receptive" to Olumiant pricing.
06/11/18
EVER
06/11/18
UPGRADE
EVER
Outperform
Incyte upgraded to Outperform from In Line at Evercore ISI
06/11/18
EVER
06/11/18
UPGRADE
EVER
Outperform
Incyte upgraded to Outperform from In Line at Evercore ISI
Evercore ISI analyst Josh Schimmer upgraded Incyte to Outperform and raised its price target to $96 from $70 saying there is too much potential value in the late stage protfolio to be ignored. Schimmer said Epacadostat issues are mostly behind the company and with clarity on Olumiant, he are returning to a constructive outlook on shares.
LLY Eli Lilly
$85.90

-0.17 (-0.20%)

06/13/18
MSCO
06/13/18
NO CHANGE
MSCO
HHS 'smoke signals' worth noting for drugmakers, says Morgan Stanley
After HHS Secretary Alex Azar spoke at a two-hour Senate hearing, Morgan Stanley analyst David Risinger noted that Azar suggested that U.S. drug pricing needs to move to a system without rebates and said payments from drugmakers to PBMs should be eliminated. In listing four HHS actions that could hurt manufacturers, Risinger pointed out that Azar said he is interested in removing 100% cap on Medicaid rebates; he would like to adjust the Part D protected drug classes so that plans can extract rebates from manufacturers; HHS wants to require manufacturers to disclose drug list prices in TV ads; and HHS is focused on transitioning Part B to lower-priced private sector management. In summary, the analyst said that for drugmakers there was "no fire, but smoke signals worth noting." Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
06/13/18
JEFF
06/13/18
DOWNGRADE
Target $50
JEFF
Hold
Armo BioSciences downgraded to Hold from Buy at Jefferies
Jefferies analyst Biren Amin downgraded Armo BioSciences (ARMO) to Hold and lowered his price target for the shares to $50 from $61. The analyst expects the takeover by Eli Lilly (LLY) to close in a few weeks and does not expect a competing bid to emerge.
MRK Merck
$61.46

0.295 (0.48%)

05/24/18
MZHO
05/24/18
NO CHANGE
Target $103
MZHO
Buy
Nektar is Bristol-Myers' best chance in immuno-oncology, says Mizuho
Nektar Therapeutics' (NKTR) NKTR-214 asset is the best shot Bristol-Myers Squibb (BMY) has to retain its footing in the competitive immuno-oncology space, Mizuho analyst Difei Yang tells investors in a research note. The analyst says that recent data in non-small cell lung cancer presented by Merck (MRK) on Keytruda saw the company jump ahead of Bristol's Opdivo in this key indication. Upcoming data of the Opdivo/NKTR-214 combo at ASCO on June 2 will be key on 100 patients across multiple indications, Yang contends. She believes Bristol stands at risk of losing significant market share in the growing immuno-oncology space. Ahead of the data, the analyst reiterates a Buy rating on Nektar with a $103 price target.
06/14/18
MSCO
06/14/18
NO CHANGE
Target $68
MSCO
Overweight
Merck Q2 estimates lowered below consensus at Morgan Stanley
Morgan Stanley analyst David Risinger cut his Q2 revenue estimate for Merck by 1% to $10.1B, which he notes is below the consensus view of $10.3B, and lowered his Q2 EPS estimate by 6% to 97c. This is below the consensus view of $1.03, which he argues "needs to come down." The two key drivers were lowering his estimates for Keytruda in the U.S. due to a more gradual ramp in first-line lung cancer patients and the negative impact of hedging, which he sees being similar to, but less pronounced, than in Q1. He lowered his full-year EPS view by only 1%, however, which puts it 2% below consensus. Risinger keeps an Overweight rating and $68 price target on Merck shares.
06/01/18
ROTH
06/01/18
NO CHANGE
Target $400
ROTH
Buy
Roth Capital ups Madrigal price target to $400, examines possible M&A scenarios
Roth Capital analyst Yasmeen Rahimi noted that Madrigal Pharmaceuticals' (MDGL) "impressive" NASH resolution results published yesterday resulted in the stock's value being pushed up to make it the highest among "purely NASH" companies. Among large pharma companies, Rahimi believes those with the strongest metabolic franchises, large R&D teams, and sales forces focused on endocrinologists, gastroenterologists, and hepatologists likely have eyes on NASH assets, listing Merck (MRK), AstraZeneca (AZN), Eli Lilly (LLY) and Novo Nordisk (NVO) as examples. The historical acquisition price for NASH assets ranges from $200M to $1.7B, but Rahimi argues that Madrigal "can set the highest NASH price tag yet," estimating a potential takeout valuation of $5.6B. Rahimi raised her price target on Madrigal shares to $400 from $210 and keeps a Buy rating on the stock.
SHPG Shire
$161.73

-0.7 (-0.43%)

05/09/18
LEER
05/09/18
NO CHANGE
LEER
Takeda/Shire transaction shows path for consolidation, says Leerink
Leerink analyst Geoffrey Porges notes that Takeda (TKPYY) confirmed its intention and agreement to purchase Shire (SHPG) for $62B in cash and stock. For the broader biopharma industry, the analyst believes Takeda's ability to lever up to an estimated 5.4x net debt/EBITDA suggests that investors are underestimating the ability of large cap biopharma companies to pursue large transactions. Nearly all of the large cap biopharma companies face looming growth issues or suffer under revenue-concentration risk discounts that could be mitigated by large-scale acquisitions, he contends. Porges believes that if Takeda can execute the Shire acquisition while checking the boxes of investor demands of a net positive ROIC, instant EPS accretion, maintaining an investment grade credit rating, and massive synergy savings, then others in the biopharma industry with stronger balance sheets and larger valuations can contemplate transactions that are substantially larger even than Shire.
04/25/18
RHCO
04/25/18
NO CHANGE
Target $205
RHCO
Buy
Shire price target raised to $205 from $190 at SunTrust
SunTrust analyst John Boris raised his price target on Shire (SHPG) to $205 and kept his Buy rating after an updated merger proposal from Takeda (TKPYY), which has until May 8th to make the final offer. Boris believes the combined stock-and-cash offer of $205 is high enough for Shire shareholders to accept the terms, and other bidders could potentially emerge based on its positive catalysts such as Neuroscience strategic review and LANA August PDUFA.
04/19/18
WELS
04/19/18
NO CHANGE
WELS
Outperform
Wells says Allergan investors likely 'relieved and confused' by Shire news
Wells Fargo analyst David Maris believes Allergan (AGN) investors will be "both relieved and confused" by the company's announcement that it was considering a bid for Shire (SHPG) being following approximately four hours later by another announcement saying that it does not intend to make an offer for Shire. After catching up with Allergan, Maris does not think the turn of events reflects a confusion or flip-flopping, but rather was the result of disclosures required by UK takeover law, and "don't reflect anything other than Allergan being caught at a bad time." He maintains an Outperform rating on Allergan shares.
04/19/18
WELS
04/19/18
NO CHANGE
Target $245
WELS
Outperform
Allergan selloff on potential Shire bid understandable, says Wells Fargo
Wells Fargo analyst David Maris believes the selloff today in shares of Allergan (AGN) on news the company is considering a bid for Shire (SHPG) is understandable. Many believe Allergan was in the process of trimming, not bulking up, Maris tells investors in a research note. He believes that if CNBC's subsequent report is true and Allergan won't be making a bid, the "about-face would be an incredible turn given Allergan's press release came out just a couple hours earlier." Further, the analyst thinks investors are now left wondering what type of disruption another major integration could mean for a company that has already had significant organizational change. Maris has an Outperform rating on Allergan with a $245 price target. The stock in afternoon trading is down 4% to $159.36.
RHHBY Roche
$0.00

(0.00%)

06/20/18
SBSH
06/20/18
NO CHANGE
Target $100
SBSH
Buy
Tesaro could be valued at $140-$213 in takeover scenario, says Citi
Citi analyst Robyn Karnauskas said that investors have been asking about her M&A analysis for Tesaro, which she has published previously. Her analysis suggests the company could be valued at $140-$213 per share in a takeover scenario, noted Karnauskas, who maintains a Buy rating and $100 price target on Tesaro shares. The questions may have increased after Spanish website Intereconomia reported that following its acquisition of Foundation Medicine (FMI), Roche (RHHBY) is working with Citibank on a potential acquisition of Tesaro, The Fly notes.
06/20/18
RBCM
06/20/18
NO CHANGE
RBCM
Sector Perform
RBC Capital 'skeptical' on 'unsubstantiated' reports Roche eyeing Tesaro buyout
RBC Capital analyst Kennen Mackay said he is "skeptical" of "unsubstantiated" media reports suggesting Roche (RHHBY) is interested in buying Tesaro (TSRO) given what he sees as lack of a compelling strategic rationale for such a deal. Given Zejula's trajectory to date and increasing competition in the recurrent maintenance ovarian cancer market, Mackay continues to expect Street estimates to be lowered for Tesaro. He also thinks Roche is focused on developing or acquiring "best-in-class" molecules, and given this context Mackay sees Rubraca as a potentially better fit than Zejula, he tells investors. Mackay keeps a Sector Perform rating and $46 price target on Tesaro shares.
06/21/18
RHCO
06/21/18
NO CHANGE
Target $150
RHCO
Buy
Tesaro takeout range is around $153 per share, says SunTrust
SunTrust analyst Peter Dawson notes yesterday's speculation in Intereconomia.com about a potential acquisition of Tesaro (TSRO) by Roche (RHHBY), saying his M&A valuation analysis puts a potential takeout value on Tesare at $153 per share or about $8.4B. The analyst says the rumor is also positive for other PARP inhibitor players like Clovis (CLVS) as well as Tesaro's oncology peers. Dawson keeps his Buy rating and $150 price target on Tesaro stock.
06/18/18
MZHO
06/18/18
NO CHANGE
Target $423
MZHO
Buy
Biogen move downward on PTC data appears overdone, says Mizuho
Mizuho analyst Salim Syed estimates that the 6% move lower in Biogen (BIIB) shares following PTC (PTCT) and Roche's (RHHBY) data on their SMA candidate implies that the consensus Spinraza worldwide peak revenue estimate should decline from a current figure of $2.5B to about $1B, which he thinks is overdone as he would argue perhaps a $500M-$750M downward adjustment is more reasonable. While risdiplam's data is good, it has only been 6 months and 21 patients and there is no comparative data in the PTC trial, he tells investors. Additionally, Spinraza has the first mover advantage and by the time PTC's drug makes it to market, doctors may be reluctant to change, added Syed. He keeps a Buy rating and $423 price target on Biogen shares, which is down 5.7% to $287.73 in late day trading.
SNY Sanofi
$39.98

0.96 (2.46%)

04/27/18
MSCO
04/27/18
NO CHANGE
Target $400
MSCO
Equal Weight
Regeneron slide after Sanofi report an overreaction, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison noted that Sanofi's (SNY) report of Q1 earnings included details on worldwide sales for Regeneron (REGN) partnered products Dupixent, Praluent and Kevzara and that all three products missed consensus estimates. He believes investors are primarily concerned by the large Dupixent miss, as its sales were about 22% below the consensus forecast. However, Sanofi indicated that patient volumes continue to trend favorably and that Dupixent was hurt by greater patient assistance and inventory drawdown in the quarter. While he understands the reaction, he also views it as overdone, Harrison said, maintaining a $400 price target and Equal Weight rating on Regeneron shares.
04/27/18
PIPR
04/27/18
NO CHANGE
PIPR
Regeneron's Q1 'won't be pretty' based on Sanofi results, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond notes that Sanofi (SNY) this morning reported Q1 results, including revenue numbers for Dupixent, Praluent and Kevzara. All three missed consensus, but importantly, demand trends appear intact for Dupixent, with its miss driven by inventory fluctuations and seasonality, Raymond tells investors in a research note on Regeneron Pharmaceuticals (REGN) titled "Sanofi Read-Through: Looks Like Q118 Won't Be Very Pretty." He has an Overweight rating on Regeneron with a $500 price target.
05/23/18
LEHM
05/23/18
NO CHANGE
Target $290
LEHM
Underweight
Regeneron product concentration remains big risk, says Barclays
Barclays analyst Geoff Meacham says his analysis suggests Eylea concentration remains a big risk for Regeneron Pharmaceuticals (REGN). A scenario analysis shows the company's adjusted earnings is sensitive to even modest changes to U.S. Eylea sales versus any product under the Sanofi (SNY) joint venture, namely Dupixent, Praluent, and Kevzara, Meacham tells investors in a research note. The analyst reiterates an Underweight rating on Regeneron with a $290 price target.

TODAY'S FREE FLY STORIES

GS

Goldman Sachs

$220.75

5.47 (2.54%)

14:07
10/16/18
10/16
14:07
10/16/18
14:07
Recommendations
Goldman Sachs analyst commentary  »

JMP Securities sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 26

    Oct

DLTR

Dollar Tree

$86.09

5.11 (6.31%)

, DG

Dollar General

$110.50

4.08 (3.83%)

14:07
10/16/18
10/16
14:07
10/16/18
14:07
Recommendations
Dollar Tree, Dollar General, Amazon.com analyst commentary  »

Reported Icahn stake in…

DLTR

Dollar Tree

$86.09

5.11 (6.31%)

DG

Dollar General

$110.50

4.08 (3.83%)

AMZN

Amazon.com

$1,808.50

47.51 (2.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 16

    Oct

  • 17

    Oct

  • 25

    Oct

CAG

Conagra Brands

$36.10

0.2725 (0.76%)

, PF

Pinnacle Foods

$66.45

0.22 (0.33%)

14:04
10/16/18
10/16
14:04
10/16/18
14:04
Conference/Events
Pinnacle Foods to host special shareholder meeting »

Special Shareholder…

CAG

Conagra Brands

$36.10

0.2725 (0.76%)

PF

Pinnacle Foods

$66.45

0.22 (0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

CRON

Cronos Group

$11.66

-0.07 (-0.60%)

14:00
10/16/18
10/16
14:00
10/16/18
14:00
Options
Cronos short-term calls active as shares see up and down action »

Cronos short-term calls…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABC

AmerisourceBergen

$90.56

0.98 (1.09%)

, WBA

Walgreens Boots Alliance

$75.52

0.8 (1.07%)

13:50
10/16/18
10/16
13:50
10/16/18
13:50
Periodicals
Walgreens CEO 'doesn't rule out' deal with AmerisourceBergen, Bloomberg says »

Walgreens (WBA) CEO…

ABC

AmerisourceBergen

$90.56

0.98 (1.09%)

WBA

Walgreens Boots Alliance

$75.52

0.8 (1.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

CJREF

Corus Entertainment

$0.00

(0.00%)

13:49
10/16/18
10/16
13:49
10/16/18
13:49
Upgrade
Corus Entertainment rating change  »

Corus Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DVMT

Dell Technologies

$95.51

0.52 (0.55%)

13:46
10/16/18
10/16
13:46
10/16/18
13:46
Periodicals
Dell still thinks offer 'in best interest of DVMT shareholders,' Bloomberg says »

Dell Technologies is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:45
10/16/18
10/16
13:45
10/16/18
13:45
General news
U.S. corporate bond update: several financials are on tap »

U.S. corporate bond…

FDC

First Data

$23.61

0.56 (2.43%)

13:40
10/16/18
10/16
13:40
10/16/18
13:40
Options
8K First Data Jan 25 - 27 call spreads trade for 55c »

8K First Data Jan 25 - 27…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 29

    Oct

  • 03

    Mar

SNE

Sony

$57.24

0.99 (1.76%)

, BTC

Bitcoin

$0.00

(0.00%)

13:35
10/16/18
10/16
13:35
10/16/18
13:35
Hot Stocks
Sony developing rights management system for digital content using blockchain »

Sony Corporation, Sony…

SNE

Sony

$57.24

0.99 (1.76%)

BTC

Bitcoin

$0.00

(0.00%)

BITCOIN

Bitcoin

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:35
10/16/18
10/16
13:35
10/16/18
13:35
General news
Treasury Option Action: 10-year positioning »

Treasury Option Action:…

TTWO

Take-Two

$131.41

3.43 (2.68%)

, ATVI

Activision Blizzard

$77.79

2.09 (2.76%)

13:31
10/16/18
10/16
13:31
10/16/18
13:31
Hot Stocks
Game On: Pachter says 'Red Dead Online' could be 25% as popular as 'GTA Online' »

Welcome to "Game…

TTWO

Take-Two

$131.41

3.43 (2.68%)

ATVI

Activision Blizzard

$77.79

2.09 (2.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

WHR

Whirlpool

$108.01

2.6 (2.47%)

13:26
10/16/18
10/16
13:26
10/16/18
13:26
Periodicals
AHAM reports U.S. shipments of major home appliances down 0.4% in September »

The Association of Home…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

SYMC

Symantec

$20.20

0.42 (2.12%)

13:25
10/16/18
10/16
13:25
10/16/18
13:25
Options
Symantec call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 06

    Dec

13:25
10/16/18
10/16
13:25
10/16/18
13:25
Conference/Events
Credit Suisse energy analysts to hold an analyst/industry conference call »

Energy Analysts, along…

SGRY

Surgery Partners

$14.56

0.34 (2.39%)

, UNH

UnitedHealth

$270.48

10.68 (4.11%)

13:21
10/16/18
10/16
13:21
10/16/18
13:21
Hot Stocks
Surgery Partners strength attributed to TheDeal.com discussion of M&A potential »

Shares of Surgery…

SGRY

Surgery Partners

$14.56

0.34 (2.39%)

UNH

UnitedHealth

$270.48

10.68 (4.11%)

HCA

HCA Healthcare

$134.76

1.9 (1.43%)

THC

Tenet

$26.32

0.69 (2.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 30

    Oct

  • 06

    Nov

IBM

IBM

$144.39

3.27 (2.32%)

, AMZN

Amazon.com

$1,799.99

39 (2.21%)

13:19
10/16/18
10/16
13:19
10/16/18
13:19
Earnings
Fly Intel: What to watch for in IBM's earnings report »

IBM (IBM) is scheduled to…

IBM

IBM

$144.39

3.27 (2.32%)

AMZN

Amazon.com

$1,799.99

39 (2.21%)

MSFT

Microsoft

$110.61

3.01 (2.80%)

ORCL

Oracle

$48.18

1.06 (2.25%)

GOOG

Alphabet

$1,117.65

25.65 (2.35%)

GOOGL

Alphabet Class A

$1,130.17

28.59 (2.60%)

GRPN

Groupon

$3.59

0.085 (2.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 17

    Oct

  • 21

    Oct

  • 22

    Oct

  • 22

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 07

    Nov

  • 13

    Nov

  • 28

    Nov

  • 03

    Mar

XENT

Intersect ENT

$28.91

-1 (-3.34%)

, REGN

Regeneron

$396.44

18.64 (4.93%)

13:18
10/16/18
10/16
13:18
10/16/18
13:18
Recommendations
Intersect ENT, Regeneron analyst commentary  »

Regeneron data won't…

XENT

Intersect ENT

$28.91

-1 (-3.34%)

REGN

Regeneron

$396.44

18.64 (4.93%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 19

    Oct

  • 20

    Oct

  • 28

    Oct

  • 06

    Nov

  • 27

    Nov

  • 28

    Apr

  • 13

    May

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
10/16/18
10/16
13:17
10/16/18
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
10/16/18
10/16
13:16
10/16/18
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DUK

Duke Energy

$81.02

0.89 (1.11%)

13:14
10/16/18
10/16
13:14
10/16/18
13:14
Hot Stocks
Duke Energy pilot program to expand EV charging across South Carolina »

As new electric vehicles…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

  • 11

    Nov

  • 11

    Nov

AAPL

Apple

$219.86

2.59 (1.19%)

, ZTCOY

ZTE Corp.

$0.00

(0.00%)

13:08
10/16/18
10/16
13:08
10/16/18
13:08
Hot Stocks
Apple, ZTE named as respondents in USITC probe of LTE, 3G cellular devices »

The U.S. International…

AAPL

Apple

$219.86

2.59 (1.19%)

ZTCOY

ZTE Corp.

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:05
10/16/18
10/16
13:05
10/16/18
13:05
General news
Euro$ interest rate futures are idling sideways »

Euro$ interest rate…

WHR

Whirlpool

$108.28

2.87 (2.72%)

13:04
10/16/18
10/16
13:04
10/16/18
13:04
Hot Stocks
Whirlpool rises to session high, up 3% »

The afternoon move higher…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

AXSM

Axsome Therapeutics

$3.38

0.04 (1.20%)

13:03
10/16/18
10/16
13:03
10/16/18
13:03
Hot Stocks
Axsome Therapeutics granted orphan status for narcolepsy treatment »

The FDA granted Axsome…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 17

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.